Prophage G-200

Prophage G-200 is an **autologous, patient-specific therapeutic cancer vaccine** generated from a patient's own surgically resected tumor tissue, primarily developed for **recurrent glioblastoma multiforme**. The vaccine is made by processing the patient’s tumor tissue to create a polyvalent vaccine containing multiple antigens unique to the patient’s tumor; these antigens, chaperoned by heat shock proteins (primarily HSPPC-96), are designed to provoke a robust, targeted immune response against the tumor upon re-administration[1][2][5][6][14]. Unlike some cellular vaccines, Prophage G-200 does not require dendritic cell isolation or cytokine supplementation (e.g., GM-CSF), simplifying preparation and administration[1][3]. The primary mechanism is activation of the patient’s own immune system, specifically T-lymphocyte-mediated cytotoxicity, targeting tumor-specific antigens. The vaccine has been investigated in phase II clinical trials for glioblastoma, both alone and in combination with checkpoint inhibitors for other tumor types such as metastatic melanoma[5][6].

Brand names

Prophage G-200

Other names

Prophage G-200G-200G200G 200Prophage Series G-200